

# SWISS BIOTECH DAY 2019

The leading Life Sciences Conference in Switzerland and  
Annual General Assembly of the Swiss Biotech Association



**7 MAY 2019**

Congress Center Basel

## Conference Guide

Organized by:



**BIOCOM.**



### **Free WiFi**

SSID: Swiss Biotech Day 2019

User-ID: 2221166316 | PW: 2706



### **Twitter**

#sbd2019

# Conference Program at a Glance

08:30	Registration open	
09:00	Exhibition & Partnering open	
<b>Room Singapore</b>		
09:30	General Assembly of the Swiss Biotech Association <i>(for SBA members only)</i>	
<b>Room Montreal</b>		
11:00	Plenary Session	page 4
13:00	Lunch	
<b>Parallel tracks in the afternoon</b>		
<b>Room Montreal</b>		
13:30	Emerging Biotech Company Presentations	page 5
16:30	Panel 8: Innosuisse Funding for your Biotech Innovation	page 9
<b>Room Singapore</b>		
13:30	Advanced Biotech Company Presentations	page 5
<b>Room Samarkand</b>		
13:30	Panel 1: Real Life and Practical Insights into Data Analysis and Augmented Reality – Industry 4.0 Case Studies	page 6
14:30	Panel 2: Cell-Based Therapeutics	page 6
15:30	Panel 3: Panel on Bioinformatics and Artificial Intelligence in Biotech	page 7
16:30	Panel 4: Philanthropic Investments in Biotech	page 7
<b>Room Osaka</b>		
13:30	Panel 5: Innovative Solutions in Financing Biotech	page 8
14:30	Panel 6: HealthCare: Italy on the Move	page 8
16:00	Panel 7: R&D Collaboration Forum with a Focus on Germany and Italy	page 9
17:30	Apéro	
19:00	End of Conference	

## Plenary Session

Room Montreal

*Moderation: Monika Jones*

### 11:00 Welcome Address

Michael Altorfer, CEO, Swiss Biotech Association

### 11:10 Keynote I: How to build a successful biotech company using the advantages Switzerland has to offer

Jean-Paul Clozel, CEO, Idorsia

### 11:30 Keynote II: Rise and Pitfalls of Swiss Biotech start-ups

Patrick Aebischer, former EPFL President

### 12:00 Presentation of the Swiss Biotech Report

Jürg Zürcher, EY

### 12:20 Swiss Biotech Success Stories

Laureates 2018/2019

### 13:00 Lunch

## Swiss Biotech Success Stories

### Demonstrating the power and potential of the Swiss biotech hub

The Swiss Biotech Success Stories illustrate the valuable accomplishments and honor those who have made important and sustainable contributions to the biotech industry in Switzerland. The recognition is awarded annually at the Swiss Biotech Day and reflects the diversity and variety of this industry sector.

### Open up your network

To ensure that the selected Swiss Biotech Success Stories are visible around the globe in many locations, media and events, you can help with your network and distribution power! Share with us your suggestions for spreading the word by e-mail to [info@swissbiotech.org](mailto:info@swissbiotech.org).

# SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring  
major achievements

Gold sponsor

 **MIRABAUD**

Silver sponsors

 **SWITZERLAND  
GLOBAL  
ENTERPRISE**  
accelerating your business

 **EY**  
Building a better  
working world

Supported by

Gebert Ruf Stiftung

Basel-Stadt

Bench International

INNOTIO

TS Kommunikation

## Emerging Biotech Company Presentations

**Room Montreal**

*Moderation: Cora Kaiser, Rentschler Biopharma*

### 13:30 **Introductory Talk**

**Daniel Mattle**, Director Business Development Europe, Rentschler Biopharma

<b>13:40</b> Abologix	<b>15:00</b> Novaremed
<b>13:50</b> AC BioScience	<b>15:10</b> PharmaBiome
<b>14:00</b> Anaveon	<b>15:20</b> PreComb Therapeutics
<b>14:10</b> ARTIDIS	<b>15:30</b> SpacePharma
<b>14:20</b> Gain Therapeutics	<b>15:40</b> Tepthera
<b>14:30</b> Versameb	<b>15:50</b> TOLREMO therapeutics
<b>14:40</b> MaxWell Biosystems	<b>16:00</b> InterAx Biotech
<b>14:50</b> Nemis Technologies	<b>16:10</b> VERSANTIS

## Advanced Biotech Company Presentations

**Room Singapore**

*Moderation: Dave Madge, WuXi Apptec*

### 13:30 **Introductory Talk**

**Dave Madge**, Vice President Research Services Division, WuXi Apptec

<b>13:45</b> Santhera	<b>15:55</b> GeNeuro
<b>14:05</b> Newron	<b>16:10</b> Genkyotex
<b>14:25</b> Addex	<b>16:25</b> Biobide
<b>14:45</b> IQVIA	<b>16:40</b> WuXi Biologics
<b>15:00</b> Jennewein	<b>16:55</b> NBE Therapeutics
<b>15:20</b> InnoMedica	<b>17:10</b> Swissfillon
<b>15:40</b> Helsinn Healthcare	<b>17:25</b> Sophia Genetics

**13:30–14:15 Panel 1**

**Room Samarkand**

**Real Life and Practical Insights into Data Analysis and Augmented Reality – Industry 4.0 Case Studies**

This session gives question and answer access to experts that truly understand the practical implications for life science with examples of the enormous opportunity for your business created by the start of the 4th Industrial Revolution.

**Moderation:** *David Staunton, Director Global Services, Zenith Technologies*

Panelists:

**Dr Martin Valek**, Digital Services, GE Healthcare Life Science

**Jacqueline Hora**, Global Digital and Data Analytics lead, Zenith Technologies

**14:30–15:15 Panel 2**

**Room Samarkand**

**Cell-Based Therapeutics**

Cell-based therapeutics offer a novel and promising approach to target a wide variety of medical conditions. However, aspects such as safety concerns, complex logistics, upscaling of manufacturing and regulatory approval are typical hurdles complicating development. This session will offer you a diverse discussion from CRO, academic and sponsor perspectives based on real-life examples ranging from recombinant live vaccines to autologous cell therapy.

**Moderation:** *Aernout van Haarst, PhD, Director Scientific Affairs, Celerion*

**Clinical Development of Cell-Based Therapeutics –**

Complexity of live product logistics | Safety aspects around cellular therapies | Implications of developing GMOs

**Aernout van Haarst**, PhD, Director Scientific Affairs, Celerion

**Tolerogenic Dendritic Cell-Based Treatment in Multiple Sclerosis (MS) –**

Manufacturing of cell-based therapies | Initial results of clinical trials involving a dendritic cell-based treatment for MS patients | Comparison of different routes of administration

**Prof. Dr. Nathalie Cools**, Associate Professor Faculty of Medicine and Health Sciences, University of Antwerp

**Master Checkpoint Cbl-b Inhibition: Ambulatory siRNA-Based Autologous Cell Therapy for Cancer –** Master checkpoint blockade regulating innate and adaptive anti-tumor responses | Preliminary evidence of phase 1 clinical activity in cancer patients

**Anderson Gaweco**, M.D., PhD, CMO & CSO, APEIRON Biologics AG, Austria

**Discussion**

**15:30–16:15 Panel 3**

**Room Samarkand**

**Panel on Bioinformatics and Artificial Intelligence in Biotech**

The panel will address questions such as: What can AI bring to the Pharma and Biotech industries specifically? Why is this a hot topic now? What will be required to ensure AI applications are robust, trusted and thus adopted?

**Moderation: Jurgi Camblong, CEO, Sophia Genetics**

**Jurgi Camblong**, CEO, Sophia Genetics

**Prof. Marcel Salathé**, School of Computer and Communication Sciences, EPFL

**Lorenz Mayr**, Chief Technology Officer, GE Healthcare Life Sciences

STETSON FAMILY OFFICE

Presented by  **Healthcare Impact Foundation**

**16:30–17:15 Panel 4**

**Room Samarkand**

**Philanthropic Investments in Biotech**

Many early stage companies face the proverbial “Valley of Death” where lack of angel/VC capital implies lack of talent and impedes the risk-mitigation of the company as a business. How could an effective philanthropy help risk mitigate this situation and attract for-profit investors into early stage companies? In translation of HC innovation, why do we need philanthropy and what type?

**Moderation: Eugène Durenard, Stetson Family Office**

Panelists:

**Richard Serbin**, Healthcare Impact Holdings and Gorlin Group of Companies

**Riccardo Braglia**, Group Vice Chairman & CEO, Board Member & US Chairman, Helsinn Healthcare

**Beat Schillig**, Founder and President, Venture Kick

**Viviane Monges**, NOVO Foundation

**13:30–14:15 Panel 5**

**Room Osaka**

**Innovative Solutions in Financing Biotech**

Fundraising, especially in early stage, is challenging for Biotech companies. With the introduction of Decentralized Ledger Technology (Blockchain) into the Capital Market Value Chain, new financing possibilities are opening such as Crypto Crowd Funding, Securities tokens or the tokenization of revenue streams. A panel of innovative finance experts will discuss if these new opportunities can be of benefit for Biotech companies.

**Moderation: Monika Jones**

**André Guedel**, Head of International Headquarters, KPMG Switzerland

**Prof. Dr. Fabian Schär**, Managing Director Center for Innovative Finance & Credit, Suisse Asset Management (Schweiz) | Professor for DLT/FinTech

**Dr. Daniel Heller**, FinTech Expert, Centre for Blockchain Technologies, University College London

**Sascha Bucher**, Head Basel Office Roivant Pharma and Head of Global Transactions

**14:30–16:00 Panel 6**

**Room Osaka**

**HealthCare: Italy on the move**

Italian startups and R&D players will provide you with insights in Italy's biotech sector. Breakthrough therapeutic solutions are in the pipeline in oncology, neurology and immunology. Team up with the country's research laboratories and clinical trial projects to be first-to-know and to contribute to the advancement of novel therapies.

**Moderation: Simona Bernardini, ITA Italian Trade Agency Bern**

**Healthcare Italy: Welcome address**, Simona Bernardini, ITA Bern

**Key Figures and Areas of Excellence of Italian Biotech**

**Leonardo Vingiani**, Assobiotech-Federchimica

**Therapeutic Solutions by Italian Biotech Star Companies**

**Altheia Science**, Multiple Sclerosis & Diabetes, Paolo Rizzardi

**Greenbone Ortho**, Bone-Reconstitution / Oncology, Giorgio Amadori

**Diatech Pharmacogenetics**, PharmacoGenetics & Personalized Therapies, Sara Cabodi

**Cancer Vaccines & Hepatocellular Carcinoma (HCC)**

**Luigi Buonaguro**, National Cancer Institute „G. Pascale“

**Approval Procedures for Novel Therapies & Clinical Trials**

**Cristina Morelli**, MTA Group

**ITA supporting BIOTECH cooperation in Italy – ONE STOP WINDOW**

**Rossana Ciraolo**, ITA Italian Trade Agency



## 16:00–17:30 Panel 7

**Room Osaka**

### R&D Collaboration Forum with a Focus on Germany and Italy

In this session you will hear about cross-border R&D collaborations as an expansion strategy for growing life sciences startups. After presenting the R&D landscapes in Switzerland, Germany and Italy, a pitch session will be followed by international startups active in fields such as AI, precision medicine, bioinformatics, biomarker and target identification, ATPMs for cell & gene therapy, molecular engineering, and biobanking & cryologistics.

**Moderation: Sirpa Tsimäl, Switzerland Global Enterprise**

Introductory Talk: **Cross-border R&D: A View from Germany**  
**Matthias Bach**, BIO Deutschland e. V.

Pitch Session Italy: Holostem, Orobix, VeraSalus Ricerca, CROS NT

Pitch Session Germany: BioVariance GmbH, BioKryo GmbH

Presented by



## 16:30–17:30 Panel 8

**Room Montreal**

### Innosuisse Funding for your Biotech Innovation

Are you interested in implementing an innovation project and are looking for support? The Innosuisse panel is an opportunity to learn more about Innosuisse's incentive offers. Those wishing to enter foreign markets will also be able to discover the Enterprise Europe Network (EEN) and Euresearch offers. The history of a successful project funded by Innosuisse will close the session.

**Moderation: Johanne Stettler, Communication specialist, Innosuisse**

**Innosuisse helps you to set up your Innovation Projects**

Learn how with **Stéphanie Lecaude**, Scientific Officer at Innosuisse

**Go global – International Programmes and Partnering Support at Innosuisse**

by **Nicolas Lentz**, Scientific Officer at Enterprise Europe Network (EEN)

**Your European opportunities in Horizon 2020**

with **Gerhard Gass**, National Contact Point Biotechnology for Euresearch program

**History of a successful project funded by Innosuisse:**



A 3D organ-on-a-chip assay that can predict the metabolic stability of pharmaceutical drugs presented by **Dr Laura Suter-Dick**, Professor of Molecular Toxicology at the FHNW and **Dr Olivier Frey**, Head of Technologies and Platforms at InSphero

# Floor Map

2<sup>nd</sup> floor



3<sup>rd</sup> floor



- Exhibitor Booths
- Partnering Booths
- Partnering Help Desk, Speaker Check-In
- Partnering Tables
- Catering

Rooms:

- Mexico Delegation South Carolina
- Hongkong Delegation ITA Italian Trade Agency
- Guangzhou Delegation ASEBIO
- Nairobi Exhibitor Service
- Rio Press Room
- Miami Conference Room

# Delegations

## South Carolina

## Room Mexiko

South Carolina (USA) is focused on building, advancing and growing the life sciences industry in this globally recognized Southeastern state. With a \$12 billion economic impact, over 400 firms and 40,000 professionals employed, South Carolina life sciences boasts innovative pharmaceutical, medical device, health IT and agricultural biotech organizations. Led by SCBIO, South Carolina's research universities, health systems, pharma and biotech organizations are leading research and development of innovative solutions that will make a difference globally. South Carolina (USA) welcomes your interest. [www.scbio.org](http://www.scbio.org)

## ITA Italian Trade Agency

## Room Hongkong

ITA Italian Trade Agency is a governmental body promoting also the connectivity between Italian tech-clusters and international partners. In the field of Health-Biotech, ITA promotes transnational cooperation in manufacturing and R&D. This is achieved by supporting match-making in Italy, and through ITA's 80 world-wide offices also internationally. ITA serves as a one-stop window for international companies requiring support in doing business in Italy.

## ASEBIO

## Room Guangzhou

ASEBIO, the Spanish Bioindustry Association, aspires to lead the transformation of our country, Spain, positioning innovation as the engine of its competitiveness and social development, thus promoting the development of the biotechnological ecosystem as a key element of this paradigm shift. At the moment, ASEBIO is one of the largest biotechnology associations in Europe with close to 300 members that include companies, clusters, foundations, universities, research and technology centers. To learn more about us: [www.asebio.com](http://www.asebio.com)

SAVE THE DATE

# SWISS BIOTECH DAY 2020

The leading Life Sciences Conference in Switzerland and  
Annual General Assembly of the Swiss Biotech Association

**21 APR 2020**

Congress Center Basel

## Are you interested in increased visibility at the next Swiss Biotech Day?

We offer various sponsorship opportunities designed to promote your brand, products, services and build partnerships.

Contact us to discuss your ideas!

You can meet our team here at the BIOCOM booth #18.

Or you can contact us at [marketing@biocom.de](mailto:marketing@biocom.de) or +41 43 508 11 21.

Organized by:

# Exhibitors

## A&M Laboratory Group



Situated in the Heart of Europe the A&M Laboratory Group offers GxP compliant analytical services Made in Germany. With 250+ dedicated scientists and technicians, state-of-the-art equipment and a 25+ year flawless track record in authority and client audits, A&M is your analytical one-stop shop for the development of your drug from discovery to manufacturing. With clients ranging from small start-ups to big pharma we could be the ideal partner for your outsourcing needs, too.

**Booth 33**

## BDO



BDO, the brand name for BDO USA LLP, is a U.S professional services firm providing assurance, tax & advisory support to clients through a global network of 80,087 experts in 162 countries. BDO's Life Sciences practice addresses the need of our clients at all stages of small molecule, vaccine, biologic & MedDev development, with extensive expertise in R&D, project & financial management & regulatory compliance for government-funded biodefense and pandemic response development.

**Booth 21**

## BioAgilytix



BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With locations in USA and Europe, its team provides PK, immunogenicity, biomarkers, and cell-based assay services supporting development and release testing of biologics across disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, and GMP quality control testing (i.e. product release testing, stability testing).

**Booth 01**

**BIOCOM**

BIOCOM is the leading communication and information company specialized on life sciences. Based on thorough analyses of the biotech, medtech and bioeconomy sectors in Europe, BIOCOM offers reports as well as customized consultancy services, surveys and research studies to clients. In communication services, clients receive everything from one source: conferences, videos, websites and brochures are not only designed, but also implemented and produced.

**Booth 18****Biomapas**

Biomapas is a functional and full outsourcing solution provider to the global life science industry, with key expertise in Clinical Trials, Regulatory Affairs and Pharmacovigilance. The company has significant presence across the CEE, Nordic and CIS countries thereby offering fast and reliable patient recruitment for Phase I-IV and medical device clinical trials, while regulatory and pharmacovigilance services are provided across 4 continents.

**Booth 06****Biopôle**

Biopôle is an innovation-oriented life sciences campus in Lausanne, bringing together a strong community of industry and academic specialists. The site houses more than 75 companies and institutions, including the head offices of multinational corporations, start-ups and clinical development teams, together with technology and service providers. It also hosts 25 world-famous research groups, such as CHUV, the University of Lausanne and the Ludwig Institute for Cancer Research.

**Booth 08****biotechnet**

The biotechnet Switzerland helps you access a wide variety of high-caliber competences in biotechnology of Swiss Universities of Applied Sciences, Universities and Research and Technology Organizations. Industrial partners including small, medium and large enterprises can rely on our proven expertise and outstanding infrastructure to support innovative research & development projects. We are also a premium partner to address continuing education needs.

**Booth 30**

## Biotechpharma



Biotechpharma is a cGMP-certified contract development and manufacturing organisation (CDMO). We specialize in producing microbial based recombinant proteins and mammalian cell culture-based monoclonal antibodies. Biotechpharma delivers a complete range of services including cell line construction & cell banking, analytical and process development and cGMP production. We ensure the highest quality service for our clients by collaborating with them from end to end utilizing the latest technology.

**Booth 02**

## CEBIS International



CEBIS International is a Swiss-Based Global CRO specialized in clinical research and regulatory services having operations in 29 countries. As a full service CRO, CEBIS is covering services like: medical writing, regulatory affairs, project management, monitoring, data management, biostatistics, and publishing. CEBIS is working closely with pharmaceutical, biotechnology, and medical devices companies.

**Booth 25**

## Celerion



Celerion, a leader in early clinical research services and clinical bioanalysis industry, is a global company with over 40 years of experience. Our unique combination of medical expertise, clinical operations experience and scientific excellence provides our customers with the confidence to make fast, accurate decisions about their drug development. Our state-of-the-art laboratories focus on science, compliance and speed to deliver high-quality data analysis.

**Booth 14 | 14:30 Room Samarkand**

## Clinmark



Clinmark is a leading Polish CRO specializing in clinical research in Europe and global clinical consulting. We have conducted more than 230 studies and performed over 350 GxP audits in 75 countries on 5 continents. Clinmark leads products from concept through non-clinical, clinical and regulatory development to marketing authorization. Services: preclinical and clinical development, GxP audits, patient recruitment support, product development plans, product registration, CE mark, training.

**Booth 32**



## Coriolis Pharma



Nova is a world leader in the development & manufacturing of advanced cell culture monitoring instruments. Nova's BioProfile® FLEX2 provides key chemistries & gases, CDV & osmolality with a single sample, & incorporates maintenance-free MicroSensor Card™ technology. FLEX2 offers online sampling from bench-scale bioreactor systems & ambr® cell culture systems. Nova's Swiss subsidiary offers a wide range of services & applicative as well as technical support to its customers.

**Booth 37**

## CRB



CRB is a leading design and consulting firm serving life science companies around the world. For more than 3 decades, we have been providing technical expertise and outstanding project execution to our clients' organizations. From small studies to large and complex process designs, we have the expertise to deliver successful solutions for the local pharmaceutical and biotechnology market.

**Booth 22**

## CROss Alliance



CROss Alliance is a top-quality CRO group devoted to clinical drug development since 1996. The group includes CROSS Research and CROSS Metrics. We own a phase I unit in CH and we perform high risk phase I trials in our partner site in Austria. Phase II and III trials are performed in collaboration with local partner CROs in Europe and managed from our team leaders based in Lugano. CROSS Metrics holds deep expertise in Data Management, Statistics and Pharmacokinetic Analysis.

**Booth 40**

## Ernst & Young



The global EY organization is a leader in assurance, tax, transaction, legal and advisory services. We leverage our experience, knowledge and services to help build trust and confidence in the financial markets and in economies all over the world. Our Life Sciences Sector brings together a worldwide network of 15,000 sector-focused professionals to anticipate trends, identify their implications and help our clients create competitive advantage. Please visit [www.ey.com/ch](http://www.ey.com/ch).

**Booth 30**

## Euresearch



Euresearch is the Swiss information network for European research and innovation programmes. On behalf of the federal government, Euresearch informs and advises interested people, organisations and companies, and promotes Swiss participation in European projects.

**Booth 12 | 16:30 Room Montreal**

## Eurogentec



Eurogentec, part of Kaneka Corporation, is a leading supplier of products and services to scientists involved in the life science research, molecular diagnostics and therapeutic developments. The international company is recognized as one of the major suppliers in the field of genomics and proteomics as well as a trusted FDA inspected CDMO for the production of biopharmaceuticals (vaccines and medicines).

Eurogentec is ISO9001 and ISO13485 certified.

**Booth 17**

## European Pharmaceutical Students' Association



European Pharmaceutical Students' Association (EPSA) represents over 100.000 pharmaceutical students from 37 European countries, bringing pharmacy, knowledge and students working together in order to promote the pharmaceutical field and collaboration between professionals involved in the healthcare system. May you be interested in partnering up with EPSA, do not hesitate to visit our website and visit section dedicated to our partners and find the opportunity that best suits you.

**Booth 30**

## Exyte



Exyte is a global leader in design, engineering and construction delivering high-tech facilities, plants and factories. With a history of more than 100 years, we have developed special expertise in controlled and regulated environments. Operating in 20 countries, we serve the most technically demanding clients in growth markets such as semiconductors, life sciences, and data centers across the full spectrum of services from consulting and design to managing turnkey solutions.

**Booth 11**

## GBA Group Pharma



From early lead optimization and early preclinical stage to global clinical studies, GBA Group Pharma supports clients throughout the entire lifecycle with central laboratory, GMP Depots, EU GMP manufacturing site for labeling and packaging and QP services, as well as late drug development and analytical services including import testing and QP batch release. GBA Group Pharma is a fully Brexit Proof Organisation as all facilities and QPs are located in mainland Europe.

**Booth 10**

## Gilson



Gilson is a family-owned global manufacturer of liquid handling, purification and extraction solutions for the life sciences industry. By partnering closely with the scientific community, we're continuously advancing our product portfolio –from manual pipetting to automated systems and to preparative liquid chromatography. Backed by worldwide R&D, service, and support, Gilson strives to enable verifiable science and make lab life easier for our customers

**Booth 41**

## Horizon Discovery



Horizon Discovery is a world leader in the utilization of gene editing and modulation technologies to support the greater understanding of gene function, the genetic drivers behind human disease and the development of personalized molecular, cell and gene therapies. Our products and services are used by thousands of scientists working in academic institutes, pharmaceutical companies and clinical diagnostic laboratories around the globe with our headquarters in Cambridge, UK.

**Booth 20**

## InnoMedica



InnoMedica is a Swiss nanomedicine company developing and commercializing a liposomal drug delivery platform. The treatment of cancer patients in the Phase I clinical trial of the lead compound Talidox is proceeding as planned in Swiss hospitals. The second pipeline product Talineuren uses the liposomal platform to deliver a neuro-stimulant substance to the brain and shows regenerative effects against Parkinson's disease in preclinical studies.

**Booth 04 | 15:20 Room Singapore**

## Innosuisse



Innosuisse is the Swiss Innovation Agency. It fund science-based innovation in the interests of industry and society with the aim of increasing the competitiveness of small and medium-sized enterprises (SMEs) in Switzerland. By promoting innovative business models and forging international partnerships, Innosuisse opens up new horizons for SMEs. Learn more about its offers.

**Booth 12 | 16:30 Room Montreal**

## IPS



IPS is a global leader in developing innovative business solutions for the biotechnology and pharmaceutical industries. Through operational expertise and industry-leading knowledge, skill, and passion, IPS provides integrated EPCMV services that allow clients to create and manufacture life-impacting products in the EMEA Region and around the world. IPS has over 1,200 professionals in the US, Canada, Brazil, United Kingdom, Ireland, Switzerland, Singapore, China, and India.

**Booth 42**

## IQVIA



IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services dedicated to using analytics and science to help healthcare stakeholders find better solutions for their patients. IQVIA offers a comprehensive set of flexible solutions: from defining the plan for your asset, to trial implementation, through launch and commercialization, IQVIA can help you find your path to success. [www.iqvia.com](http://www.iqvia.com).

**Booth 19 | 14:45 Room Singapore**

## JAG



JAG is a leading process technology company which designs and builds the most challenging and highly automated process plants for the pharmaceutical and biotech industries. Our plants are among the world's most efficient. Using the JAG PdiCS automation solution, we can fully automate even the largest and most challenging production processes in the pharmaceutical and biotech industry and provide for maximum productivity.

**Booth 28**

## Jennewein Biotechnologie GmbH



Jennewein Biotechnologie GmbH is a leading company specializing in the production of rare functional monosaccharides and oligosaccharides for nutritional, pharmaceutical, cosmetic and medical applications. The company manufactures an extensive portfolio of human milk oligosaccharides. Their human milk oligosaccharides are produced using the latest fermentation technology. Jennewein received approval for the HMO 2'-fucosyllactose in the US in 2015 and in the EU in 2017.

**Booth 24 | 15:00 Room Singapore**

## Legacy Pharmaceuticals Switzerland



Legacy Pharmaceuticals Switzerland is a Swiss contract manufacturer and service provider (CMO) for the global pharmaceutical industry specialized in aseptic Fill&Finish. Created in 2007, the company was originally founded in 1947, back to the years when the modern Swiss pharmaceutical industry was just getting started. With SWISSMEDIC, EMEA, US FDA, and PMDA approvals, the company is able to meet the stringent regulatory requirements in the various markets around the world.

**Booth 31**

## Life Science Zurich Young Scientist Network



The Life Science Zurich Young Scientist Network (LSZYSN) is a non-profit organisation managed by PhD students and Post-docs mainly from the University of Zurich and ETH Zurich. Our mission is to bridge the gap between academia and the life science industries. To achieve this, the LSZYSN is engaged in a wide range of activities aiming to build sustainable relationships with life sciences/healthcare companies and to provide a basis for young university graduates to transition from academia to these companies.

**Booth 30**

## LYO-X



LYO-X is a Basel based company providing Systems Pharmacology and mathematical PK/PD modelling services for biotechnology and venture capital companies. LYO-X's expertise are novel therapeutic formats: antibodies, bi-specifics, antibody-drug conjugates (ADCs), fusion proteins, peptides, gene therapies and siRNAs. LYO-X is one of the few providers worldwide in this nice domain and has been supporting over 90 companies globally in translating their highly innovative therapeutic molecules into patients

**Booth 09**

## MLM Medical Labs



MLM Medical Labs is a GLP-certified, CLIA-, CAP- and ISO15189 accredited central laboratory dedicated exclusively to clinical trials. We offer full laboratory services, incl. a whole range of analytics: standard safety profiles, analyses of biomarkers, drug compounds, metabolites and molecular diagnostic parameters. Our over 75-person team supports between 140 and 150 clinical studies, Phase I-IV. Internationally active in over 40 countries we are located in Mönchengladbach, Germany.

**Booth 03**

## MyData-TRUST



MyData-TRUST supports the Life Sciences Industry in leveraging Data Protection compliance: GDPR, HIPAA, Privacy Shield and Swiss DPA. The aim of MyData-TRUST consists in providing strategic, operational and organizational support, making an important contribution both legally and technically to the success of the Data Protection implementation and the company as a whole.

**Booth 29**

## Morgan Sindall



Morgan Sindall is an integrated engineering provider of consulting, design, project management, asset life cycle management and beyond. Our extended experience in the biotech, pharma, fine chemicals and energy sectors make our know-how unique and enable us to provide our customers with fully-integrated, complete and tailored solutions. Our top-notch performance and one-stop-shop characteristics have made us a leading engineering partner in the D-A-CH Region.

**Booth 05**

## Newcells Biotech



Newcells Biotech develops in vitro cell based assays for pre-clinical drug discovery. Using its core technology based on induced pluripotent stem cells (iPSCs) the company provides safety, ADMET and disease modelling services and products. The company has developed and launched assays for measuring drug kidney transport and nephrotoxicity. Assays using iPSC technology include a 3-D model of the human retina and models of the inner ear and the lung epithelium.

**Booth 44**

## Nova



Nova is a world leader in the development & manufacturing of advanced cell culture monitoring instruments. Nova's BioProfile® FLEX2 provides key chemistries & gases, CDV & osmolality with a single sample, & incorporates maintenance-free MicroSensor Card™ technology. FLEX2 offers online sampling from bench-scale bioreactor systems & ambr® cell culture systems. Nova's Swiss subsidiary offers a wide range of services & applicative as well as technical support to its customers.

**Booth 13**

## ProPharma Group



ProPharma Group is an international, independent, single-source provider of comprehensive compliance services that span the entire lifecycle of pharmaceuticals, biologics, and medical devices. With extensive experience managing global projects, as well as product portfolios for local markets, our experts provide an unmatched variety of compliance related services including regulatory affairs, life science consulting, medical information, and pharmacovigilance.

**Booth 38**

## PSI CRO



PSI CRO is a privately-owned, full-service clinical research organization (CRO) operating globally. PSI's global reach supports clinical trials across multiple countries and continents and is known to be highly selective about the work that they pursue. With an exceptionally high repeat and referral business rate combined with minimal staff turnover, PSI is committed to being the best CRO in the world as measured by its customers and its employees.

**Booth 27**

## Rentschler Biopharma



Rentschler Biopharma SE is a leading contract development and manufacturing organization (CDMO), focused exclusively on clients' projects. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. Rentschler Biopharma is a family-owned company employing more than 850 people. The company is headquartered in Laupheim, Germany and has a biopharma site in Milford, MA, USA.

**Booth 36 | 13:30 Room Montreal**

## Retrogenix



Retrogenix provides a fast, accurate and effective solution for primary receptor identification and specificity screening of antibodies, protein ligands, CAR T cells, viruses and small molecules. Physiologically relevant targets are identified by screening for interactions against a comprehensive set of plasma membrane proteins and secreted proteins expressed in the context of human cells.

**Booth 39**

## Schmidt Versicherung



We're among the very few broking firms in Switzerland experienced in handling life science companies – for example those involved in biotech, implants and pharmaceuticals. Working in close co-operation with specialised underwriters we provide tailor-made solutions for our clients. As a result Schmidt Versicherungs Treuhand AG is well on the way to becoming one of the leading broking firms in the field.

**Booth 23**

## Swiss Private Equity & Corporate Finance Association



The Swiss Private Equity & Corporate Finance Association (SECA) is the representative body for Switzerland's private equity, venture capital and corporate finance industries. SECA has the objective to promote private equity and corporate finance activities in Switzerland. Members of the SECA include equity investment companies, banks, corporate finance advisors, auditing companies, management consultants, lawyers and private investors.

**Booth 30**

## SIX



SIX operates one of the most important European stock exchanges. It offers outstanding liquidity in trading of Swiss and foreign securities and connects companies from around the world with international investors and trading participants. As a self-regulated exchange, it is able to provide particularly market-friendly conditions for listing and trading in equities, bonds, ETFs, ETPs, mutual funds and structured products.

**Booth 15**



**Socorex**

Swiss manufacturer of precision liquid handling instruments: Electronic & manual micropipettes, repeater pipettes, bottle-top dispensers, electronic & manual pipette controllers, self-refilling syringes and consumables. Instruments operate under standards such as ISO 8655, GLP, GMP. Each instrument passes a strict quality control, attested by an individual QC certificate. Pipette lines bear the CE mark (IVD 98/79/CE conform). ISO 17025 accredited control laboratory.

**Booth 07****SSS International Clinical Research**

With an expertise of more than 25 years in conducting clinical studies, we can provide our clients with advice in a broad range of important aspects – feasibility, submission strategy, patient recruitment, risk-based monitoring, final study report – to name only a few. Longstanding cooperation with industry leaders gives us cutting edge knowledge in strategic, regulatory and operational aspects of clinical research.

**Booth 35****Swiss Biotech Association**

Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.

**Booth 30****Swiss HLG**

Swiss HLG is a group of Senior Business Development Executives working together to serve those actively involved in BD&L and deal-making. The association is open to the international healthcare and life sciences industries. It provides the richest possible environment to network, build strategic relationships, exchange ideas and to share experiences. Swiss HLG has about 150 members, has delivered 29 industry conferences and has an excellent reputation for quality.

**Booth 30**

## Venturelab/Venture Kick



Venturelab/Venture Kick: Together with successful founders, leading academic and industry partners, Venturelab designs and operates programs to support the best startup talents in closing their financing rounds and to accelerate their global business development. The fully private and philanthropic foundation Venture Kick paid out 25 million francs in start capital to 600 high-tech and life science startups since 2007. 75 new projects will receive support totalling 4.35 million francs in 2019. **Booth 30**

## YUMAB



YUMAB develops fully human antibodies for partners worldwide. The YUMAB® platform covers technologies from antibody discovery to antibody engineering and lead optimization. Its in vitro and on-cell selection technologies provide high success-rates to all types of antigens. YUMAB antibodies contain natural, close to germline sequences promising low immunogenicity and toxicity. Bioinformatic optimization and in vitro evolution technologies give direct access to optimized leads. **Booth 34**

## Zenith Technologies



Zenith Technologies are world leaders in delivering manufacturing software systems that make Life Sciences compliant and competitive. We specialise in implementing and supporting Automation, MES and Digital solutions. With experience in the delivery and management of over 35 technologies covering: MES, DCS, PLC / SCADA, Historian, PAT & BMS, we deliver performance improvements, reduced costs & total compliance for pharma and biotech companies globally. **Booth 26 | 13:30 Room Samarkand**

## ZETA group



The ZETA group is one of Europe's largest provider of engineering, automation and process technology for biopharmaceutical aseptic applications. The product range extends from streamlined engineering project execution to state-of-the-art customized process systems for biologic drug substance production plants.

**Booth 43**

# Notes

# Presenting Companies

## Abologix



Abologix was founded out of research from the Univ of Geneva on the therapeutic potential of inhibiting “Junction Adhesion Molecule – C” (JAM-C). There is no cure for the treatment of Mantle Cell lymphoma (MCL). 75% of MCL patients express JAM-C, not only at diagnosis, but also after treatment and at relapse. Abologix has developed monoclonal antibody H255, directed against JAM – C. Abologix is opening a financing round to invest in the development of H255.

**13:40 | Room Montreal**

## AC BioScience



AC BioScience SA is a biotech company dedicated to developing innovative therapies to fight infectious and inflammatory diseases, and companion products for the treatment of tumoral and immunological pathologies. The company has three potential blockbuster candidates under development of which one - as a repurposed drug - has already advanced to a clinical stage. The company identifies and develops only compounds with a previous history of successful pre-clinical results.

**13:50 | Room Montreal**

## Addex



Addex Therapeutics is a company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional „orthosteric“ biological drugs. Founded in 2002, Addex is based in Geneva and listed on the SIX Swiss Stock Exchange under the trading symbol ADXN.

**14:25 | Room Singapore**

## Anaveon



Anaveon is developing a selective IL-2 Receptor agonist, a protein that enhances a patient's immune system to respond to tumors. Anaveon's product is designed to overcome known challenges of recombinant IL-2. These include lack of selectivity, severe side effects and short half-life requiring frequent infusions. This type of drug, if approved, could have a wide utility in oncology, including in combination with cell therapies, vaccines, checkpoint inhibitors and radiotherapy. **14:00 | Room Montreal**

## ARTIDIS



ARTIDIS has developed a nanomechanical biomarker and is applying its technology platform of precise tissue measurement and data analytics in order to personalize diagnosis and treatment of cancer. The technology is currently being validated in a blinded clinical study on > 500 patients at the University Hospital Basel for breast cancer. A multi-centre study (Europe, US) will be launched soon to test its platform in a neoadjuvant therapy setting for breast and lung cancer. **14:10 | Room Montreal**

## Biobide



Biobide is a leading CRO with more than 14 years of experience in zebrafish alternative model for early discovery and development. Biobide offers high quality and tailor-made assays in toxicity, efficacy, target validation and disease model generation carried out according to the principle of the 3Rs and GLP environment. All the know-how acquired during years allows to predict toxicities in a cost-time effective manner, such as teratogenicity, cardiotoxicity or neurotoxicity. **16:25 | Room Singapore**

## Gain Therapeutics



Gain Therapeutics SA is a biotech company developing next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using a proprietary platform technology (SEE-Tx®). The company has currently several discovery programs in lysosomal storage diseases and CNS indications at various preclinical stages of development. Gain was founded in 2017 by experienced biotech and pharma entrepreneurs. [www.gaintherapeutics.com](http://www.gaintherapeutics.com) **14:20 | Room Montreal**

## GeNeuro



GeNeuro is focused on stopping neurodegenerative and autoimmune diseases through targeting causal factors of these pathologies by leveraging the emerging biology of human endogenous retroviruses (HERVs), retroviral DNA insertions that account for 8% of the human genome. GeNeuro has Phase II clinical programs in multiple sclerosis and type 1 diabetes, and earlier stage programs in other areas of high unmet medical need such as amyotrophic lateral sclerosis.

**15:55 | Room Singapore**

## Genkyotex



Genkyotex is the leading biopharmaceutical company in NOX therapies, listed on Euronext Paris and Brussels. Its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The lead product candidate, GKT831, is evaluated in a Ph2 trial in PBC and in an investigator-initiated Ph2 trial in DKD.

**16:10 | Room Singapore**

## Helsinn Healthcare



Helsinn is a privately-owned pharmaceutical group with a strong development pipeline, 700 employees globally, committed to improving the quality of life of patients affected by cancer through the development of innovative therapeutic and supportive care products. Through its unique B2B and B2C business model, Helsinn's products are distributed in 190 countries, with a direct presence in US and China, thanks to our expertise in R&D, manufacturing, and licensing.

**15:40 | Room Singapore**

## InterAx Biotech



InterAx Biotech is uniquely positioned to assist GPCR drug candidate design and selection by integrating bioanalytical and computational pharmacology in collaborative projects with biotech and pharma companies. InterAx applies mathematical models and simulations to in house-derived experimental data in order to address the complexity of drug-induced cellular signaling mechanisms. Our goal is to close the gap between laboratory experiments and in vivo studies.

**16:00 | Room Montreal**

## MaxWell Biosystems



MaxWell Biosystems provides advanced high-resolution electrophysiology platforms to facilitate detailed investigation of excitable cells in vitro. MaxOne and MaxTwo allow to stimulate and record from every active cell on a dish at unprecedented spatial and temporal resolution. Every cell has a story to tell. MaxWell Biosystems' aim is to empower everyone with systems that enable easy access to cells and fast discovery of cells' function.

**14:40 | Room Montreal**

## NBE Therapeutics



NBE-Therapeutics is a Swiss Biotech company developing immune-stimulatory antibody drug conjugate (iADCTM) products. The company leverages a suite of proprietary technology platforms, including antibody discovery, site-specific conjugation and linker-payload technologies to develop next-generation iADC product candidates. NBE-Therapeutics is financially backed by the Boehringer Ingelheim Venture Fund, PPF Capital Partners Fund, Novo Holdings and additional private investors.

**16:55 | Room Singapore**

## NEMIS Technologies



NEMIS Technologies is a Swiss diagnostics company in the field of rapid, precise, easy-to-use and low-cost screening detection of pathogenic bacteria. In response to the rapidly growing global challenge, our patented AquaSparkTM technology offers a simple and powerful phenotypic point-of-care diagnostic solution to prevent the proliferation of dangerous bacteria in the fields of food safety, clinical diagnostics, water safety or animal health.

**14:50 | Room Montreal**

## Newron



Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. In its pipeline: Xadago® (Adjunctive therapy in PD) commercialized by Newron's partners in the EU, Switzerland and US; sarizotan (Rett syndrome); ralfinamide (rare pain indications) and Evenamide (adjunctive therapy in schizophrenia and Clozapine TRS). [www.newron.com](http://www.newron.com)

**14:05 | Room Singapore**

## Novaremed



Novaremed AG is a Swiss biopharmaceutical company developing a small molecule (NRD.E1) with a novel mechanism of action to treat Diabetic Neuropathic Pain. In a Phase 2a Proof of Concept study, NRD.E1 has shown clinically relevant reduction in patient reported pain. Novaremed is currently preparing to conduct a global Phase 2b study expected to start in Q4 2019. Novaremed has raised CHF18.4 million to date from private investors. Novaremed is currently raising CHF25 million.

**15:00 | Room Montreal**

## PharmaBiome



PharmaBiome pioneers next-generation microbiome therapies. Our bacterial mixes target functional disbalances of the gut – an underlying cause of incurable diseases like ulcerative colitis. Our deep understanding of previously uncultured intestinal bacteria and a proprietary mixed-culture technology allow unprecedented control over production and therapeutic efficacy. PharmaBiome's scalable and versatile pipeline allows the fast development of a diversified product portfolio.

**15:10 | Room Montreal**

## PreComb Therapeutics



PreComb Therapeutics AG is a privately held Swiss biotech company focused on in vitro cancer diagnostic to improve cancer management. It's automated microtumor-based profiling device will enable clinical institutions to integrate the technology on-site in the hospital. The test makes it possible to functionally evaluate multiple cancer drugs, drug combinations and drug concentrations directly on patient-derived microtumors to maximize treatment outcome.

**15:20 | Room Montreal**

## Santhera



Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company with a portfolio of innovative medicines for rare neuro-ophthalmologic, neuromuscular and pulmonary diseases. In Europe, idebenone is marketed as Raxone® for Leber's hereditary optic neuropathy and in regulatory pre-submission as Puldysa® for Duchenne muscular dystrophy. The pipeline includes rights to vamorolone for DMD, POL6014 for cystic fibrosis and omigapil for congenital muscular dystrophy.

**13:45 | Room Singapore**



## Sophia Genetics



We believe in building a more sustainable global healthcare system. That's why we developed SOPHiA AI, the advanced technology for Data-Driven Medicine, that enables healthcare institutions around the world make sense of genomic and radiomic data, empowering clinical researchers to leverage their expertise and work as a community. Adopted by more than 950 hospitals in 80 countries, SOPHiA has already supported the diagnosis of more than 330,000 patients worldwide. **17:25 | Room Singapore**

## SpacePharma



SpacePharma provides researcher, institutes and commercial companies an easy and affordable access to the microgravity environment. Our novel technology enables researchers to perform complex chemical and biological experiments with our proven cutting-edge remote-control technology and labs in space. **15:30 | Room Montreal**

## Swissfillon



Swissfillon AG is an agile fill & finish contract manufacturing organization (CMO) for complex pharmaceutical and biopharmaceutical products. Swissfillon provides highest quality and security drug product manufacturing services to its clients from clinical phase to commercial supply. Major specialization is on small-medium batch-size manufacturing. **17:10 | Room Singapore**

## Tepthera



Tepthera's fundament is a set of proprietary platform technologies allowing efficient identification of disease relevant T cell antigens. These antigens will provide the basis for developing personalized therapies in various medical fields such as infectious diseases, autoimmunity and foremost in cancer immunotherapy. The broad applicability of the platform is opening multiple opportunities to develop new therapeutics in house and through collaborations. **15:40 | Room Montreal**

## TOLREMO



There is a high unmet need for durable therapeutic options for cancer patients. Although cancer drugs relieve patients from their tumor burden, they oftentimes lose their effectiveness over time. TOLREMO develops novel small molecules that eradicate drug resistant cancer cells right at the start of a therapy. TOLREMO's resistance-braking add-on therapies can be combined with existing cancer drugs to meaningfully extend the lives of cancer patients.

**15:50 | Room Montreal**

## Versameb



Versameb Ltd. is a biopharmaceutical company located in Basel, Switzerland, operational since the beginning of 2018. The company employs a team of highly experienced professionals in life science industry. Versameb's proprietary platform technology enhances the local application of functional mRNA in different disease contexts. The current development focus is on regenerative medicine indications, and we explore the potential of mRNA in other therapeutic areas.

**14:30 | Room Montreal**

## VERSANTIS



Versantis is a clinical-stage pharmaceutical company focused on the development of orphan drugs in liver diseases. Our mission is to support acute hepatic decompensations and to save children born with rare genetic disorders. Versantis' lead candidate VS-01 is being investigated in a Ph1b clinical trial on severe cirrhotic patients, a stepping stone towards two high-value orphan indications in the acute care for which Versantis plans to commercialize VS-01 is less than 3 years.

**16:10 | Room Montreal**

## WuXi AppTec



WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company. Innovation-driven and customer-focused, WuXi AppTec provides a broad and integrated portfolio of services to help our customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. Please visit: [www.wuxiappotec.com](http://www.wuxiappotec.com)

**13:30 | Room Singapore**

## WuXi Biologics



WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our achievements demonstrate our commitment to providing a truly ONE-stop service offering to our global clients. For more information on WuXi Biologics, please visit [www.wuxibiologics.com](http://www.wuxibiologics.com). **16:40 | Room Singapore**

## Further Sponsors

### EuroScienceJobs

### Euro★ScienceJobs

EuroScienceJobs – Focused Jobsite for Scientific Researchers. Over two thirds of EuroScienceJobs' users have a PhD in science, in biochemistry, molecular biology, microbiology, biotechnology, biostatistics/informatics, medicine, immunology, toxicology, pharma, etc. Universities, Research Centres, Companies, Government and International Organisations recruit scientists through EuroScienceJobs. Over 60'000 e-mails are sent every week to newsletter and job-alert subscribers.

### KPMG



KPMG is a leading professional services firm in Switzerland. Through its strong regional presence KPMG is close to you, helping you navigate today's turbulences to find tomorrow's answers. In audit, tax and advisory, KPMG is noted for clear and consistent solutions. KPMG's life sciences experts have a deep understanding of the industry to support companies in challenges around cost & efficiency, valuation & financing or regulatory compliance. <http://kpmg.ch/lifesciences>

**13:30 | Room Osaka**

### OPIS



OPIS is a European clinical CRO. In addition to phase I-IV drug-related trials, OPIS also manages clinical investigations for medical and diagnostic devices and nutraceutical/food supplement studies. OPIS covers all major therapeutic areas and full-service projects are executed in compliance with regulatory requirements, ICH-GCP E6 guidelines. The OPIS EDC solution Clinical.net is FDA 21 CFR Part 11 compliant and fully customizable to digitally manage all clinical trial data.

## Switzerland Global Enterprise



Switzerland Global Enterprise (S-GE) Investment Promotion provides information to foreign companies about the particular strengths and operating conditions of Switzerland. Together with the Swiss cantons, S-GE assists potential foreign investors in the site selection process and in establishing an operation in Switzerland, providing market analysis and coordinating the activities of all parties involved in the promotion of Switzerland as a business location.

**16:00 | Room Osaka**

## TecoMedical



TECOmedical develops and offer an extensive range of FDA and EMA approved biomarkers for research, pre-clinical and clinical studies. Biomarkers for biosafety and research studies: Hemocompatibility related to activation of the complement-C system. Cytotoxicity and drug-induced liver and kidney injury testing as well as Apoptosis for Anti-Cancer Agent testing. Furthermore, TECOmedical offers customized test development: ADA, immunogenicity and host cell protein assays.

# Thanks to our Sponsors!



## Supporting Partners:



## Media Partners:

